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The aging-associated increase of cancer risk is linked with stromal fibroblast senescence
and concomitant cancer-associated fibroblast (CAF) activation. Surprisingly little is known
about the role of androgen receptor (AR) signaling in this context. We have found
downmodulated AR expression in dermal fibroblasts underlying premalignant skin cancer
lesions (actinic keratoses and dysplastic nevi) as well as in CAFs from the 3 major skin
cancer types, squamous cell carcinomas (SCCs), basal cell carcinomas, and melanomas.
Functionally, decreased AR expression in primary human dermal fibroblasts (HDFs) from
multiple individuals induced early steps of CAF activation, and in an orthotopic skin cancer
model, AR loss in HDFs enhanced tumorigenicity of SCC and melanoma cells. Forming a
complex, AR converged with CSL/RBP-Jk in transcriptional repression of key CAF effector
genes. AR and CSL were positive determinants of each other’s expression, with BET
inhibitors, which counteract the effects of decreased CSL, restoring AR expression and
activity in CAFs. Increased AR expression in these cells overcame the consequences of
CSL loss and was by itself sufficient to block the growth and tumor-enhancing effects of
CAFs on neighboring cancer cells. As such, the findings establish AR as a target for stroma-
focused cancer chemoprevention and treatment.
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Introduction
The aging-associated increase of many cancer types has been linked 
with stromal fibroblast senescence and concomitant production 
of diffusible growth factors, cytokines, and extracellular matrix/
remodeling proteins (1) that are similarly induced in cancer-asso-
ciated fibroblasts (CAFs) (2). However, fully established CAFs show 
no signs of senescence and are often characterized by increased cell 
proliferation (3, 4), consistent with a multistep process of CAF acti-
vation associated with cancer/stromal cell expansion (5).
Alterations of key regulators of transcription and chromatin 
organization involved in early steps of CAF activation include down-
modulation of CSL/RBP-Jκ (subsequently called CSL), the key effec-
tor of Notch signaling endowed with intrinsic transcriptional-repres-
sive function and overall determinant of chromatin configuration (5, 
6). CSL functions as a direct negative regulator of many CAF effector 
genes and at the same time binds to p53, suppressing its activity (5). 
As a consequence, decreased CSL levels in stromal fibroblasts result 
in the concomitant induction of CAF effector genes and p53-depen-
dent cellular senescence, with decreased p53 expression and activity 
occurring as a second step leading to full CAF activation (5).
The impact of hormonal signaling on CAF activation has been 
scarcely studied. Among hormones, androgens play an important 
role in both males and females as determinants of systemic func-
tions such as metabolism and immune system (7, 8). In addition, 
they have a significant impact on tissue processes such as angio-
genesis (9), muscle strength, wound healing, and brain activi-
ty (10–12). The role of androgens in prostate cancer is well doc-
umented (13), and there is emerging evidence that they are also 
implicated in female tumors, specifically breast cancer (14).
The androgen receptor (AR) has highly context-dependent 
functions (15). Surprisingly few studies have focused on its role in 
CAFs, so far limited to prostate cancer with apparently conflicting 
conclusions (16–21). In a mouse model, loss of stromal AR was 
reported to limit prostate cancer lesions, while, in human tumors, 
lower stromal AR expression was associated with a lower degree 
of cancer cell differentiation and poor prognosis (18).
Like AR, the biological functions of Notch/CSL signaling are 
highly context dependent (22). So far, only an indirect interplay 
between AR and Notch signaling has been reported in cellular sys-
tems unrelated to CAF activation (23, 24). Here we show that, in 
dermal fibroblasts, AR and CSL physically converge on negative 
control of key senescence and CAF effector genes. These findings 
are of functional and clinical significance, as stromal AR expres-
sion is coordinately downmodulated with CSL at premalignant 
stages of cancer development (actinic keratoses, dysplastic nevi), 
and, in an orthotopic model, decreased AR expression in dermal 
fibroblasts promotes tumorigenicity of both skin squamous cell 
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op frequently in photo-aged skin (25). To assess possible cancer 
field effects on stromal AR expression, we examined relatively 
large excisions of two AK lesions and surrounding flanking skin, 
quantifying immunofluorescence AR signal intensity in dermal 
fibroblasts within several topographically delimited areas at vari-
ous distances from the lesions. As shown in Figure 1A and Supple-
mental Figure 1A (supplemental material available online with this 
article; https://doi.org/10.1172/JCI99159DS1), we found consis-
tently decreasing AR levels in dermal fibroblasts underneath the 
lesions as compared with those further away. A similar approach 
was adopted for “topographical quantification” of AR levels in 
stromal fibroblasts underlying 2 dysplastic nevi versus skin fur-
carcinoma and melanoma cells. Conversely, increased AR expres-
sion in CAFs overcomes the consequences of CSL loss and sup-
presses the growth/tumor-promoting effects that these cells have 
on neighboring cancer cells. As such, AR is a novel potential target 
for stroma-focused cancer chemoprevention and treatment.
Results
Decreased AR expression triggers early steps of CAF activation. The 
skin provides a benchmark for studies on the interplay between 
stromal changes and early steps of cancer development. The role 
of AR signaling in this context is largely unknown. Actinic kerato-
ses (AKs) and dysplastic nevi are precancerous lesions that devel-
Figure 1. Stromal AR levels are reduced in skin cancer fields. (A) Top panels: Double immunofluorescence (IF) analysis of topographically delimited stro-
mal areas (numbered boxes) at various distances from the skin actinic keratosis (AK) lesion from patient 1, with anti-AR (red) and anti-vimentin (green) 
antibodies. Scale bar: 200 μm. Representative high-magnification IF images used for quantification of AR fluorescence signal in vimentin-positive fibro-
blasts cells. Scale bar: 20 μm. Bottom panels: Quantification of AR fluorescence signal in vimentin-positive cells within each delimited area from 2 differ-
ent patients. Values for each individual cell are indicated with mean ± SD. Less than 5% of cells double-stained for vimentin and the CD68 macrophage 
marker in parallel sections (data not shown). The H&E staining and additional IF images are shown in Supplemental Figure 1A. (B) Top panels: Triple-IF 
analysis of topographically delimited stromal areas (numbered boxes) at various distances from dysplastic nevus lesion from patient 1, with anti–melan-A 
(red), anti-AR (magenta), and anti-vimentin (green) antibodies. Scale bar: 200 μm. Representative high-magnification IF images used for quantification of 
AR fluorescence signal in fibroblasts (vimentin-positive and melan-A–negative cells). Scale bar: 20 μm. Bottom panels: Quantification of AR fluorescence 
signal in the fibroblasts within each delimited area from 2 different patients. Values for each individual cell are indicated with mean ± SD. The immunohis-
tochemical staining and additional IF images are shown in Supplemental Figure 1B.
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level by immunofluorescence analysis of HDFs versus SCC- and 
melanoma-derived CAFs (Figure 3, E and F, and Supplemental 
Figure 2, A and B).
To assess the functional significance of these findings, we eval-
uated the consequences of AR knockdown. Silencing of the gene in 
several HDF strains resulted in increased expression of α-smooth 
muscle actin (αSMA), a well-established marker of CAF activation 
(Supplemental Figure 2C), which was paralleled by induction of a 
battery of CAF effector genes (Figure 4, A and B). Induction of such 
genes occurred also upon AR gene silencing in lung fibroblasts and 
in pancreatic stellate cells (Supplemental Figure 3, A and B).
Paralleling the above findings, treatment of several HDF strains 
with flutamide, a nonsteroidal antagonist that competes with andro-
gens for AR binding and activation (26), also induced expression of 
CAF effector genes (Figure 4C), which were instead suppressed by 
treatment with AR agonists such as dihydrotestosterone (DHT) or 
MK-2866 (SARM) (Figure 4D and Supplemental Figure 3C). No 
suppressing effects were observed in CAFs even after prolonged 
DHT treatment for 3 or 7 days, consistent with the low AR levels 
present in these cells (Supplemental Figure 3, D and E).
Early steps of CAF activation and stromal fibroblast senes-
cence are closely intertwined events. As upon CSL knockdown (5), 
AR silencing in multiple HDF strains resulted in reduced prolifer-
ation and increased senescence (Figure 5, A and B). This was par-
ther away. Even in these cases, there was a progressive decrease 
in AR expression in stromal fibroblasts underlying the lesions ver-
sus those in areas further away (Figure 1B and Supplemental Fig-
ure 1B). Diminished AR expression in lesion-adjacent fibroblasts 
was confirmed by analysis of additional AK and dysplastic nevus 
samples (with a calculation of the statistical significance of the 
observed differences for all lesions; Figure 2, A and B), as well as of 
several skin squamous cell carcinomas (SCCs) and basal cell car-
cinomas (BCCs) relative to cancer-free skin of the same patients 
excised at the end of the surgical procedure (“dog ears”) (Figure 
2, C and D, and Supplemental Figure 1C). This analysis could not 
be extended to invasive melanoma lesions because of overlap-
ping melanocyte and fibroblast markers hampering unequivocal 
cell identification in tissue sections. Diminished AR expression 
was further confirmed at the mRNA level, by fluorescence-guid-
ed laser capture microdissection (LCM) and quantitative reverse 
transcriptase PCR (RT-qPCR) analysis of SCC-associated stromal 
fibroblasts, in which CAF markers like IL6 (interleukin-6) and 
POSTN (periostin) were also increased, versus dog-ears fibro-
blasts of the same patients (Figure 2E).
Decreased AR level was also observed by immunoblot analy-
sis of multiple strains of human dermal fibroblasts (HDFs) versus 
CAFs derived from SCCs, BCCs, or melanomas (Figure 3, A–D). 
Differences in AR expression were also confirmed at the cellular 
Figure 2. AR expression is downmodulated in stromal fibroblasts of premalignant and malignant skin cancer lesions. (A–D) Quantification of immunofluores-
cence analysis of AR signal intensity in vimentin-positive stromal cells underlying actinic keratoses (AK) (A), dysplastic nevi (DN) (B), squamous cell carcinomas 
(SCC) (C), and basal cell carcinomas (BCC) (D) lesions versus flanking skin from multiple patients. For A and B quantification, the same lesions as in Figure 1A 
plus those of an additional patient were used for independent quantification of AR signal intensity in lesion-adjacent areas versus flanking skin. For C and D, 
stromal cells in SCC- and BCC-adjacent areas versus flanking skin of the same patients excised at the end of the surgical procedure (“dog ears”) were used for 
quantification. Values for each individual cell are indicated with mean ± SD. Representative lower- and higher-magnification images for SCC samples are shown 
in Supplemental Figure 1C. n(vimentin-positive cells per sample) = 25 for A and B, = 20 for C and D; ***P < 0.005, 2-tailed paired t test. (E) Fluorescence-guided 
laser capture microdissection (LCM) of fibroblast (PDGFRα-positive) cells from stroma of SCC lesions versus flanking skin of the same patients was analyzed by 
RT-qPCR for the indicated genes. Values for each patient are indicated as dots with mean ± SD. n(patients) = 6; ***P < 0.005, 2-tailed paired t test.
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Increased p53 expression by AR silencing is of functional signifi-
cance, as silencing of the gene overcame the growth-suppressing 
effects of AR knockdown (Figure 6D). Molecularly, induction of 
CDKN1A was abrogated by concomitant AR and TP53 silencing, 
while the upregulation of the IL6 CAF effector gene occurred to an 
extent similar to or greater than that seen in controls (Figure 6E), 
consistent with previous findings that p53 functions as a transcrip-
tional repressor of CAF effector genes (5, 27).
Thus, downmodulation of AR expression or activity is sufficient 
to trigger early steps of CAF activation, with concomitant induction 
of CAF effector genes and p53-dependent cellular senescence.
alleled by strong suppression of p105-Rb phosphorylation (Ser780 
and Ser795), decreased levels of phospho-H3 and PCNA, and 
downmodulation of the MKI67 and c-MYC proliferation marker 
genes, while gene expression of cyclin-dependent kinase inhibi-
tors (CDKN1A and CDKN2B) was induced (Figure 5, C and D).
Together with the above changes, p53 expression was enhanced 
in HDFs with silenced AR at both protein and mRNA levels (Figure 
6, A and B). Chromatin immunoprecipitation (ChIP) assays with 3 
different HDF strains showed AR binding to 2 consensus-binding 
sites present in the TP53 gene promoter and proximal regulatory 
region, pointing to p53 as a direct negative AR target (Figure 6C). 
Figure 3. Reduction of AR protein levels is conserved in skin cancer–derived CAFs. (A and B) Immunoblot analysis of AR and CSL levels in CAF strains 
derived from multiple skin SCCs and flanking unaffected skin from matched (A) or unmatched donors (B). The blots were sequentially probed with 
antibodies against AR, CSL, and β-actin. (C and D) Immunoblot analysis of AR (C and D) and CSL (D) levels in multiple CAF strains derived from BCC (C) 
and melanoma (D) lesions versus a reference set of HDF strains. In the case of melanoma-derived CAFs, samples were run in parallel with an extract of 
melanoma cells (SK-MEL-23), and the blot was also probed with antibodies against the melanocyte/melanoma marker MITF, to verify that CAF cells were 
stromal derived (MITF negative). Additionally, DNA sequencing analysis showed oncogenic BRAF or NRAS mutations in the excised melanomas but not in 
the CAFs derived from these lesions (data not shown). (E and F) Quantification of immunofluorescence analysis of AR expression in multiple CAF strains 
derived from skin SCC (E) or melanoma (F) versus a reference set of HDF strains. Values for each individual cell are indicated with mean ± SD. Twenty cells 
per strain were counted. Representative images are shown in Supplemental Figure 2A. n(HDF strains) = 3, n(SCC-derived CAF strains) = 3, n(melanoma-de-
rived CAF strains) = 5; ***P < 0.005, 2-tailed unpaired t test.
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The strong downmodulation of AR in melanoma-derived 
CAFs suggested that it could be of functional significance also 
for this tumor type. To test this possibility, HDFs with or with-
out AR silencing were admixed with SK-MEL-23 melanoma cells 
concomitantly expressing 2 fluorescent protein indicators of 
different phases of the cell cycle (Figure 8A and Supplemental 
Figure 6C; ref. 28). Monitoring of the fluorescent signals every 3 
days for 4 weeks showed much greater expansion of melanoma 
cells in the presence of HDFs with AR silencing versus control 
(Figure 8A). Enhancement of tumor formation by HDFs with 
silenced AR was also observed in similar experiments with a 
second melanoma cell line, SK-MEL-28 (Figure 8B). Combined 
immunofluorescence and histochemical analysis of the lesions 
showed a parallel increase of melanoma cell density and prolif-
erative index, as assessed by the MITF and Ki67 markers, respec-
tively, as well as the lentivirally transduced GFP indicator of the 
S/G2 phases of the cell cycle (ref. 28; Figure 8, C and D; and Sup-
plemental Figure 6, A–C). These were associated with increased 
macrophage recruitment and vascularization, as assessed by 
immunofluorescence for the CD68 and CD31 markers, respec-
tively (Supplemental Figure 6, D and E).
Thus, in an orthotopic model of skin cancer, AR loss in dermal 
fibroblasts significantly promotes growth of SCC and melanoma 
cells, enhancing at the same time angiogenesis and inflammation.
HDFs with reduced AR expression promote SCC and melanoma for-
mation. An important question was whether loss of AR expression, as 
observed in CAFs from skin SCCs and melanomas, is of functional 
significance in vivo. We addressed this question using an orthotopic 
model of skin cancer formation (5), based on mouse ear injections 
of cancer cells in combination with HDFs with or without AR gene 
silencing. HDFs with silenced AR significantly enhanced tumor for-
mation of skin-derived SCC cells (SCC13) relative to control HDFs 
(Figure 7A). The Ki67 proliferative index of cancer cells was increased 
by HDFs with silenced AR (Figure 7B), while squamous differentia-
tion markers (K10 and filaggrin) were reduced (Figure 7, C and D). 
Consistent with the in vitro results, in vivo HDFs with silenced AR 
also showed enhanced αSMA positivity and periostin production 
(Figure 7, E and F) and p53 upregulation (Supplemental Figure 4A). 
Lesions formed in the presence of AR-silenced fibroblasts were also 
characterized by increased macrophage infiltration as well as angio-
genesis, as assessed by immunofluorescence with the CD68 and 
CD31 markers, respectively (Supplemental Figure 4, B and C).
Similar in vivo ear injection assays were repeated with anoth-
er SCC cell line (CAL27) admixed with HDFs with or without AR 
knockdown. Lesions formed in the presence of fibroblasts with 
silenced AR were characterized by a higher cancer cell prolifera-
tive index and enhanced periostin deposition, macrophage infil-
tration, and angiogenesis (Supplemental Figure 5, A and D).
Figure 4. AR is a negative regulator of CAF effector genes. (A) RT-qPCR analysis of the indicated CAF effector genes in 3 HDF strains stably infect-
ed with 2 different AR-silencing lentiviruses (sh AR1, AR2) versus control vector (sh CT). Values for each strain are indicated as dots with mean ± SD. 
n(HDF strains) = 3; *P < 0.05, ***P < 0.005, 1-way ANOVA with Dunnett’s test. (B) Immunoblot analysis of periostin and IL-6 levels in 2 HDF strains with 
AR-silencing lentiviruses (sh AR1, AR2) versus control vector (sh CT). Blots were sequentially probed for AR, periostin, IL-6, and β-actin. (C and D) RT-qPCR 
analysis of IL6, POSTN (C and D), and MMP3 (C) mRNA levels in 3 HDF strains treated with the AR antagonist flutamide (FLU; 1 μM, for 48 hours) (C) or 
with the AR agonist dihydrotestosterone (DHT; 20 nM, 24 hours) (D) in parallel with ethanol (EtOH) vehicle alone. Values for each patient are indicated as 
dots with mean ± SD. Treatment with AR agonist MK-2866 in HDFs and DHT in CAFs is shown in Supplemental Figure 3, C–E. Flutamide treatment, n(HDF 
strains) = 3; DHT treatment, n(HDF strains) = 3; **P < 0.01, ***P < 0.005, 2-tailed unpaired t test.
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AR and CSL converge on negative control of CAF activation. AR 
controls transcription in both a positive and a negative manner (15). 
By RNA-Seq analysis, we found a consistent up- and downregulation 
of several hundred genes in 2 different HDF strains with AR silenc-
ing versus controls (Supplemental Table 1). Gene ontology analysis 
showed that upregulated genes were significantly enriched for func-
tions related to extracellular matrix, wounding, and immune and 
inflammatory responses, while downregulated genes were enriched 
for nuclear functions related to nucleosome organization, transcrip-
tion, and other nuclear and RNA biosynthetic processes (Supple-
mental Figure 7A and Supplemental Table 1).
Gene set enrichment analysis (GSEA) allows an unbiased 
comparison of gene expression profiles with previously estab-
lished gene signatures (29). Using this approach, we found a sig-
nificant association between the profile of upregulated genes in 
HDFs with AR knockdown and a signature of CAF effector genes 
as well as a more extended signature of CSL gene silencing, a 
critical repressor of CAF activation (refs. 5, 6 and Supplemental 
Figure 7B). In keeping with this finding, the profile of upregu-
lated genes in HDFs with AR knockdown was also significantly 
associated with other signatures of relevance to CAF activation 
under CSL control in HDFs (ref. 5 and Supplemental Table 2).
TGF-β signaling is a key pathway leading to CAF activation in 
multiple organs/compartments (2). Besides CAF effectors, direct 
comparison of RNA-Seq profiles of HDFs with AR versus CSL silenc-
ing pointed to the TGFBR1 gene as a common AR and CSL target. 
RT-qPCR and immunoblot analysis confirmed that TGFBR1 expres-
sion is induced in HDFs upon AR and CSL silencing and showed that 
it is also upregulated in CAFs (Supplemental Figure 8, A–D). TGFBR1 
levels were also increased in dermal fibroblasts underlying SCC and 
AK lesions, by LCM/RT-qPCR analysis and immunofluorescence, 
respectively (Supplemental Figure 8, E and F).
The above results raised the possibility that AR and CSL con-
verge on transcriptional control of CAF activation. We found that 
the promoter and upstream regulatory regions of various CAF 
effector genes such as IL6, POSTN, PLOD2, FAP, and TGFBR1 
harbor a clustering of predicted AR and CSL binding sequences 
(Figure 9, A and B; Supplemental Figure 8G; and Supplemental 
Figure 9A). ChIP assays of multiple HDF strains cultured in char-
coal-stripped medium (to remove serum-bound testosterone) with 
or without DHT treatment showed ligand-dependent binding of 
AR to the predicted sites (Figure 9, A and B; Supplemental Figure 
8G; and Supplemental Figure 9A). In parallel, we found increased 
activated histone marks at these sites in HDFs with AR silencing 
Figure 5. AR gene silencing in HDFs reduces proliferation and induces senescence. (A) Growth curve of 3 HDF strains with AR-silencing lentiviruses (sh 
AR1, AR2) versus control vector (sh CT). An equal number of cells were plated onto dishes 9 days after lentiviral infection and antibiotic resistance selection, 
followed by cell number determination at the indicated times (days) after plating. Data are expressed as mean values of the 3 strains ± SD. n(HDF strains) 
= 3; ***P < 0.005, 1-way ANOVA with Dunnett’s test. (B) Left: EdU labeling assays of 3 HDF strains 10 days after infection with AR-silencing lentiviruses 
(sh AR1, AR2) versus control vector (sh CT). Right: Senescence-associated β-galactosidase staining of 3 HDF strains with AR-silencing lentiviruses (sh AR1, 
AR2) versus control vector (sh CT) 10 days after lentiviral vector infection. At least 200 cells per condition were scored. Values for each strain are indicated 
with mean ± SD. n(HDF strains) = 3; **P < 0.01,***P < 0.005, 1-way ANOVA with Dunnett’s test. (C) Immunoblot analysis of 2 HDF strains infected with 
AR-silencing lentiviruses (sh AR1, AR2) versus control vector (sh CT), with antibodies against the indicated proteins. Blots were sequentially probed with 
antibodies against phospho-Ser795 RB, phospho–Ser780 RB, phospho-H3, RB, and γ-tubulin. A separate membrane was probed with antibodies against 
PCNA and β-actin. (D) RT-qPCR analysis of the indicated genes in 3 HDF strains infected with AR-silencing lentiviruses (sh AR1, AR2) versus control vector 
(sh CT). Values for each strain are indicated with mean ± SD. n(HDF strains) = 3; *P < 0.05, **P < 0.01, ***P < 0.005, 1-way ANOVA with Dunnett’s test.
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(Supplemental Figure 9B) and in CAFs compared with matched 
HDFs (Supplemental Figure 9C). Further ChIP and re-ChIP 
assays, based on sequential immunoprecipitation with antibodies 
against CSL and AR, showed parallel binding of the AR and CSL 
proteins to many of these sites with concomitant binding to some 
of them (Figure 9C and Supplemental Figure 8H).
Such close and concomitant binding of AR and CSL to 
common sites suggested that the 2 proteins can be part of the 
same complex. In fact, an AR-CSL association could be easi-
ly visualized by proximity ligation assays (PLAs), using HDFs 
with silenced CSL as specificity control (Figure 10A). Similar 
assays were repeated with HDFs cultured in medium with char-
coal-treated serum, and with or without DHT treatment, show-
ing that AR-CSL association is ligand dependent (Figure 10B). 
Consistent with their decreased AR and CSL levels, the number 
of PLA-positive puncta was markedly reduced in a set of CAFs 
when compared with matched normal skin HDFs derived from 
the same patients (Supplemental Figure 10A).
Coimmunoprecipitation experiments with antibodies against 
either AR or CSL followed by reciprocal immunoblotting confirmed 
association of the 2 endogenous proteins in HDFs (Figure 10C). In 
addition, 2 long noncoding RNAs (lncRNAs) involved in control of 
chromatin organization that directly interact with AR, HOTAIR and 
SRA (steroid receptor RNA activator) (30, 31), were also found to 
associate with CSL, while no association was found with an unrelat-
ed lncRNA, H19, or GAPDH mRNA control (Figure 10D).
Thus, AR converges with CSL in negative control of CAF effec-
tor genes as part of the same complex.
Concordant downmodulation of AR and CSL in CAFs and coun-
teracting impact of BET inhibitors and AR overexpression. Robust 
biological systems depend on coordinated control of key network 
elements. Parallel downmodulation of AR and CSL in dermal 
fibroblasts underlying premalignant and malignant skin cancer 
lesions and various CAFs raised the possibility of a reciprocal 
cross-regulation. Immunoblot and RT-qPCR analysis showed 
consistent suppression of AR expression, at both mRNA and pro-
Figure 6. AR represses TP53 gene activation. (A) Immunoblot analysis of p53 expression in 2 HDF strains infected with AR-silencing lentiviruses versus con-
trol vector. Blots were sequentially probed with antibodies against phospho–Ser15 p53, AR, p53, and β-actin. (B) RT-qPCR analysis of TP53 expression in 3 HDF 
strains infected with AR-silencing lentiviruses versus control vector. Values for each strain are indicated as dots with mean ± SD. n(HDF strains) = 3; *P < 0.05, 
1-way ANOVA with Dunnett’s test. (C) ChIP at TP53 promoter, using anti-AR antibodies in parallel with nonimmune IgGs. Data are expressed as relative 
fold enrichment over IgGs, and values for each strain are indicated as dots with mean ± SD. Statistical significance was calculated between AR enrich-
ment at the indicated sites relative to the flanking control region. n(HDF strains) = 3; *P < 0.05, ***P < 0.005, 1-way ANOVA with Dunnett’s test. (D) EdU 
labeling assays of 3 HDF strains stably infected with a TP53-silencing retrovirus (sh TP53) versus control vector (sh CT), with or without subsequent AR 
gene silencing for 10 days, scoring at least 200 cells per condition. Values for each strain are indicated as dots with mean ± SD. Statistical significance was 
calculated on differences in changes caused by AR silencing in cells with versus without TP53 silencing or in cells with versus without concomitant AR and 
TP53 silencing. n(HDF strains) = 3; ***P < 0.005, 1-way ANOVA with Dunnett’s test. (E) RT-qPCR analysis of the indicated genes in 3 HDF strains infected 
as in D with a TP53-silencing retrovirus (sh TP53) versus control vector (sh CT), with or without subsequent AR gene silencing. Values for each strain are 
indicated as dots with mean ± SD. n(HDF strains) = 3; *P < 0.05, **P < 0.01, ***P < 0.005, 2-tailed unpaired t test.
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we previously reported in HDF with decreased CSL levels (6). In 
fact, ChIP analysis of HDFs with CSL gene silencing versus con-
trols showed an increase of the repressive histone mark H3K9Me3 
and a decrease of the active histone mark H3K27Ac at the AR pro-
tein levels, in multiple HDF strains with CSL knockdown (Figure 
11, A and B). As CSL functions as a repressor of transcription, the 
concomitant downmodulation of AR expression is likely to occur 
through an indirect mechanism and epigenetic changes like those 
Figure 7. HDFs with reduced AR expression favor SCC cell growth in vivo. (A) EGFP-expressing SCC13 cells were admixed with 2 different HDF strains with 
silenced AR versus control, followed by parallel injections into contralateral ears of NOD/SCID/IL2rg–/– mice (8–10 weeks old, females). Left: Representative 
images of combined bright-field and fluorescence microscopy of 1 pair of mouse ear lesions, at 21 days after injection. Scale bar: 1 mm. Right: Quantification of 
tumor volumes (V = length × width × 0.5) formed in the presence of HDFs with silenced AR versus control. Data are represented as mean ± SD. n(tumor pairs) 
= 9; ***P < 0.005, 2-tailed paired t test. (B) Immunofluorescence analysis and quantification of Ki67- and keratin-positive cells in lesions formed by SCC13 cells 
admixed with HDFs with or without AR silencing. Shown are representative images and quantification for 3 ear pairs, examining at least 4 independent fields 
per lesion, using ImageJ software for determination of Ki67/keratin–double-positive cells. Scale bar: 30 μm. Data are represented as mean ± SD. n(tumor pairs) 
= 3; *P < 0.05, 2-tailed paired t test. (C–F) Immunofluorescence analysis and quantification of the indicated markers in lesions formed by SCC13 cells admixed 
with HDFs with or without AR silencing. Shown are representative images and quantification for 3 ear pairs, examining at least 4 independent fields per lesion, 
using ImageJ software. Scale bars: 60 μm. Values are expressed as percentage of surface area positive for the indicated markers. Data are represented as mean 
± SD. n(tumor pairs) = 3; *P < 0.05, ***P < 0.005, 2-tailed unpaired t test. Additional data for p53, macrophage, and angiogenesis markers and further in vivo 
experiment with CAL27 SCC cells are shown in Supplemental Figures 4 and 5.
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impact of chromatin modifications on the basal transcription com-
plex (6). GSEA analysis of the gene expression profiles of several CAF 
strains treated with JQ1 showed a suppression of the AR gene silenc-
ing signature (Supplemental Figure 11A). Underlying these changes, 
we found that treatment of CAF as well as HDF strains with JQ1 and 
2 other BET inhibitors (iBET-762 and OTX-015) under clinical trials 
(32) induced AR expression at both the mRNA and protein levels (Fig-
ure 12, A–C, and Supplemental Figure 11, B–D).
We previously reported that topical treatment with JQ1 in the 
mouse ear orthotopic model suppresses CAF activation and SCC 
cell expansion (6). Similar assays with SK-MEL-23 melanoma cells 
admixed with CAFs showed even more pronounced effects of JQ1 
treatment, with strong suppression of tumor growth that made 
moter region, with reduced POLII recruitment and a decrease of 
the elongation histone mark H3K36Me in the transcribed gene 
body region (Figure 11C).
An attractive possibility was also that AR expression in turn con-
trols CSL expression. In fact, combined immunoblot and RT-qPCR 
analysis showed that in multiple HDF strains AR gene silencing 
caused a consistent downmodulation of CSL expression only at the 
protein level, without any effects on the mRNA (Figure 11, D and E).
Further studies on joint control of AR and CSL expression will 
have to be separately pursued. Here we focused on the possible trans-
lational implications of the findings for reversion of the CAF pheno-
type. The global effects of CSL loss on CAF activation are counter-
acted by treatment with BET protein inhibitors that interfere with the 
Figure 8. HDFs with reduced AR expression sustain melanoma cell growth in vivo. (A) SK-MEL-23 melanoma cells expressing a fluorescent indicator of 
cell cycle (GFP-FUCCI protein for S/G2 phases of the cell cycle) were admixed with HDFs with silenced AR versus control, followed by parallel injections 
into contralateral ears of NOD/SCID/IL2rg–/– mice (8–10 weeks old, females). Shown are representative images of combined bright-field and fluorescence 
microscopy of a pair of mouse ears, at 27 days after injection, with quantification of the green fluorescence intensity signal (intensity × surface area) at 
the indicated time points after signal normalization on day 1. Scale bar: 1 mm. Data are represented as mean ± SEM. n(tumor pairs) = 3; *P < 0.05, 2-tailed 
paired t test. (B) SK-MEL-28 melanoma cells expressing dsRed were admixed with HDFs with silenced AR versus control, followed by parallel injections into 
contralateral ears of NOD/SCID/IL2rg–/– mice (8–10 weeks old, male). Shown are representative images of combined bright-field and fluorescence microsco-
py of a pair of mouse ears, at 28 days after injection, with quantification of the red fluorescence intensity signal (intensity × surface area) at the indicated 
time points after injection after signal normalization on day 1. Scale bar: 1 mm. Data are represented as mean ± SEM. n(tumor pairs) = 5; ***P < 0.005, 
2-tailed paired t test. (C and D) Immunofluorescence analysis for the MITF and Ki67 markers in lesions formed by SK-MEL-23 cells admixed with HDFs with 
or without AR silencing. Shown are representative images and quantification for 3 tumor pairs, examining at least 4 independent fields per lesion, using 
ImageJ software. Values are expressed as number of MITF-positive melanoma cells per square millimeter (C) and percentage of Ki67-positive cells (D). 
Data are represented as mean ± SD. n(tumor pairs) = 3; *P < 0.05, 2-tailed paired t test. Scale bars: 30 μm. Representative H&E staining and additional 
macrophage and angiogenesis markers are show in Supplemental Figure 6.
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was also unaffected or even induced by AR overexpression (Figure 
13, A and B), indicating that increased AR levels can suppress CAF 
effector genes, short-circuiting the consequences of CSL loss.
In parallel with the above results, AR overexpression sup-
pressed the ability of CAFs to enhance proliferation and stem cell 
potential of neighboring SCC13 cancer cells, as assessed by con-
ventional cocultures and 3D sphere-forming assays, respectively 
(Figure 13, C and D). Even in vivo, tumorigenic expansion of SCC13 
cells was significantly decreased when they were admixed with 
AR-overexpressing CAFs in comparison with controls (Figure 14A). 
This was accompanied by a lower proliferative index of cancer cells 
and enhanced squamous differentiation with reduced CAF marker 
expression, angiogenesis, and macrophage infiltration (Figure 14, 
B–F, and Supplemental Figure 12, B and C).
it difficult to obtain tissue sections of the JQ1-treated lesions for 
analysis (Figure 12D). Importantly, JQ1 treatment of SK-MEL-23 
cells in vitro did not significantly affect their growth (Supplemen-
tal Figure 11, E and F), pointing to the importance of the impact of 
this compound on tumor–stromal cell interaction.
To assess whether increased AR expression is by itself sufficient 
to reproduce the BET inhibitor impact on CAFs, we infected these 
cells with an AR-overexpressing lentivirus. Increased AR expres-
sion resulted in the consistent suppression of multiple CAF effector 
genes that are induced by AR and CSL loss (Figure 13, A and B, and 
Supplemental Figure 12A). Importantly, downmodulation of these 
genes by increased AR levels occurred in the absence of CSL upreg-
ulation, which was rather suppressed. Concomitantly, expression of 
the HES1 gene, a negative CSL target in fibroblasts and CAFs (5), 
Figure 9. AR and CSL converge on negative control of CAF effector genes. (A) Top: Map of predicted AR and CSL binding sites (gray and red arrowheads, 
respectively) on the selected regions of the IL6 gene encompassing the promoter and a distant enhancer. Areas enriched for the H3K4Me3 (dark green) and 
H3K4Me1 (light green) histone marks (obtained from ENCODE tracks for HDFs) are also indicated. s1–s5 indicate the sites selected for analysis. Bottom: 
ChIP assay at the indicated sites of the IL6 gene, as shown in the previous panel, together with a region 11 kb upstream from the transcription start site 
devoid of AR recognition sequence as negative control (ct), using 3 different HDF strains cultured in charcoal-stripped medium (to remove serum-bound 
testosterone) with or without treatment with DHT (10 nM, 24 hours). Data are expressed as relative fold enrichment over IgGs, and values for each strain 
are indicated as dots with mean ± SD. Statistical significance of differences in AR enrichment with versus without DHT treatment at the indicated sites 
was calculated. n(HDF strains) = 3; *P < 0.05, ***P < 0.005, 2-tailed unpaired t test. (B) Map of predicted AR and CSL binding sites on the POSTN promoter 
regulatory region and determination of AR binding by ChIP in the absence or presence of the AR agonist DHT (10 nM, 24 hours) as in A. n(HDF strains) = 
3; *P < 0.05, **P < 0.01, ***P < 0.005, 2-tailed unpaired t test. (C) Determination of CSL and CSL-AR binding on the indicated sites of the IL6 and POSTN 
genes, by ChIP and re-ChIP assays based on immunoprecipitation with anti-CSL antibodies alone or sequentially with anti-AR antibodies (white and gray 
bars, respectively). Data are expressed as relative fold enrichment over IgGs. Additional ChIP data are available in Supplemental Figures 7–9.
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We focused on skin cancer, as a benchmark of major clinical 
significance for cancer development. We found that AR levels 
are downmodulated in CAFs derived from all 3 major skin cancer 
types, SCC, BCC, and melanoma, and are already reduced in stro-
mal fibroblasts underlying premalignant AK and dysplastic nevus 
lesions. Decreased AR expression is of functional importance as it 
is sufficient to trigger dermal fibroblasts to CAF activation, with 
consequent enhancement, in an orthotopic model of both SCC 
and melanoma tumor expansion.
The AR protein can act as either repressor or activator of 
gene transcription, depending on cell type, target genes, and 
proteins with which it associates (15). Loss of AR expression in 
multiple independent HDF strains, from both male and female 
donors, led to induction of key CAF effector genes, with a simi-
lar induction in fibroblasts from other body sites, indicating that 
AR is likely to play a general repressive function in CAF activa-
Thus, AR is coordinately controlled with CSL, and its upregu-
lation is of translational significance for suppression of CAF acti-
vation and stroma-focused anticancer intervention.
Discussion
Conversion of stromal fibroblasts into CAFs is likely to occur as a 
multistep process with concomitant deregulation of several path-
ways (2, 5, 6, 33). Surprisingly, the impact of hormone signaling in 
this context has been explored to a very limited extent (7). AR is 
functionally involved in various aspects of cell and tissue homeo-
stasis in organs with both reproductive and nonreproductive 
functions (15). Levels of androgens decline with age (34), suggest-
ing that decreased AR signaling contributes to various aspects of 
the aging process, including tissue atrophy and impaired meta-
bolic functions (34, 35). Whether decreased AR signaling is also a 
determinant of cancer risk remains to be established.
Figure 10. AR and CSL physically interact in primary HDFs. (A) Proximity ligation assays (PLAs) with antibodies against AR and CSL of 2 HDF strains 
with or without CSL gene silencing as specificity control. Red fluorescence puncta resulting from the juxtaposition of anti-AR and anti-CSL antibodies 
were visualized by confocal microscopy with concomitant DAPI nuclear staining. Shown are representative images and quantification of number of 
puncta per cell. Scale bar: 10 μm. Values of PLA puncta for each individual cell are indicated with mean ± SD. n(cell measurements per condition) = 35; 
***P < 0.005, 2-tailed unpaired t test. (B) PLAs with antibodies against AR and CSL in 3 HDF strains in the absence or presence of the AR agonist DHT 
(10 nM, 24 hours). Scale bar: 10 μm. Values of PLA puncta for each individual cell are indicated with mean ± SD. n(HDF strains) = 3, n(CAF strains) = 3; 
***P < 0.005, 2-tailed unpaired t test. Additional PLAs carried out in HDFs versus CAFs are shown in Supplemental Figure 10. (C) Reciprocal coimmu-
noprecipitation assays of CSL and AR association. HDF total cell extracts were immunoprecipitated with anti-AR or anti-CSL rabbit polyclonal antibod-
ies or nonimmune IgG (mock). Immunoblotting was carried out with anti-AR or anti-CSL mouse monoclonal antibodies. (D) Total cell extracts of 2 HDF 
strains and WI38 lung fibroblasts were processed for RNA immunoprecipitation with anti-CSL antibodies versus nonimmune IgGs. Immunoprecipitat-
ed RNAs were analyzed by RT-qPCR with specific primers for HOTAIR lncRNA, SRA lncRNA, H19 lncRNA, and GAPDH mRNA. Results are expressed as 
fold enrichment in immunoprecipitates with anti-CSL antibodies versus nonimmune IgG (dashed line), and values for each HDF strain are indicated as 
dots with mean ± SD. n(fibroblast strains) = 3; ***P < 0.005, 2-tailed unpaired t test.
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The functional involvement of AR loss in early steps of CAF acti-
vation is strikingly similar to that of CSL. Reduction of both AR and 
CSL expression leads to p53-dependent cellular senescence. Mecha-
nistically, while CSL inhibits p53 activity through direct binding (5), 
AR suppresses p53 expression, with p53 as direct negative target. AR 
and CSL converge also on negative control of CAF effector genes, 
binding concomitantly to neighboring sites. Physical association of 
the 2 proteins, as detected by proximity ligation and coimmunopre-
cipitation assays, suggests that they are part of a common transcrip-
tion-repressive complex, which is ligand dependent. In support of 
this possibility, HOTAIR and SRA, 2 regulatory lncRNAs that interact 
with AR (30, 31), were found to associate also with CSL.
AR and CSL are concomitantly reduced at early steps of CAF 
activation. Parallel downmodulation of the two can be reinforced 
by the reciprocal regulatory loop that we have uncovered, whereby 
silencing of one gene resulted in suppression of the other. As CSL 
functions as a repressor of gene transcription, concomitant down-
modulation of AR must occur through an indirect mechanism 
tion. Paralleling the genetic findings, treatment of normal fibro-
blasts with flutamide, a selective antagonist that competes with 
androgens for AR binding and activation (26), resulted in induc-
tion of CAF effector genes, while expression of these genes was 
suppressed by AR agonists.
While androgen signaling promotes differentiation in normal 
prostate tissue (36), androgen deprivation therapy (ADT) is the 
mainstay treatment of metastatic prostate cancer (26). Even in this 
context, however, inhibition of AR signaling has been reported to 
promote rather than suppress malignant progression of prostate 
cancer cells (37) and prostate cancer relapse through an impact on 
T cell activation (38), a concern that may extend to cancer stromal 
fibroblasts. In this context, we also note a reported association 
between melanoma incidence and previous history of prostate can-
cer, even if it was not determined whether prostate cancer patients 
were subjected to ADT (39, 40). In addition, a positive correla-
tion between ADT of prostate cancer patients and subsequently 
increased incidence of colorectal cancer was reported (41, 42).
Figure 11. Reciprocal regulation of AR and CSL 
expression in HDFs. (A) RT-qPCR analysis of AR 
mRNA expression in 3 independent HDF strains 
stably infected with 2 different CSL-silencing 
lentiviruses (sh CSL1, CSL2) versus control vector 
(sh CT). Values for each strain are indicated 
as dots with mean ± SD. n(HDF strains) = 3; 
***P < 0.005, 1-way ANOVA with Dunnett’s 
test. (B) Immunoblot analysis of AR levels in 
2 HDF strains stably infected with 2 different 
CSL-silencing lentiviruses (sh CSL1, CSL2) versus 
control vector (sh CT). Blots were sequentially 
probed for AR, CSL, and β-actin. (C) ChIP assay 
determination of H3K9Me3, H3K27Ac, POLII, 
and H3K36Me binding to the AR promoter and 
transcribed gene body regions (identified by 
ENCODE) in 2 HDF strains with or without CSL 
gene silencing. Data are expressed as relative 
fold enrichment over IgGs, and values for each 
strain are indicated as dots with mean ± SD. 
n(HDF strains) = 2. (D and E) Analysis of CSL 
expression by RT-qPCR (D) and immunoblotting 
(E) of multiple HDF strains stably infected with 
2 AR-silencing lentiviruses (sh AR1, AR2) versus 
control vector (sh CT). For RT-qPCR analysis, 
values for each strain are indicated as dots with 
mean ± SD. n(HDF) = 3. Blots were sequentially 
probed for CSL and β-actin.
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AR expression was sufficient to short-circuit CSL loss and suppress 
CAF tumor-enhancing properties. AR is a highly studied target of 
pharmacological intervention (43, 44), and compounds leading to 
its increased expression and/or activity open new possibilities for 
stroma-focused cancer prevention and treatment.
Methods
Cell culture, cell manipulations, and treatments. HDFs, CAFs, and 
SCC13, CAL27, 293T, SK-MEL-28, and SK-MEL-23 cells were main-
tained in DMEM (Thermo Fisher Scientific) supplemented with 10% 
(vol/vol) FBS (Thermo Fisher Scientific) and 1% penicillin/streptomy-
including reported changes in other transcription factors and/or 
chromatin configuration (6). AR silencing resulted in decreased 
CSL expression only at the protein level, pointing to an impact 
on post-transcriptional control of this protein, through scarcely 
understood mechanisms that need to be further investigated.
Emerging evidence indicates that CAF activation is the result 
of an epigenetic process amenable to pharmacological interven-
tion. In this context, treatment with BET inhibitors, which coun-
teract the global gene expression changes caused by compromised 
CSL function in CAFs (6), restored AR expression in these cells. 
The findings are of likely translational significance, as increased 
Figure 12. BET inhibitor treatment rescues AR expression in CAFs. (A) RT-qPCR analysis of AR mRNA expression in 7 SCC-derived CAF strains treated with JQ1 
(100 nM) versus DMSO vehicle alone for 24 hours. Values for each strain are indicated as dots with mean ± SD. n(CAF strains) = 7; *P < 0.05, 2-tailed unpaired 
t test. (B) Immunoblot analysis of AR expression in multiple CAF strains derived from SCC (CAF8–CAF10), BCC (BCAF6 and BCAF8), and melanoma lesions 
(MCAF603 and MCAF527) treated with JQ1 (100 nM) versus DMSO vehicle alone for 24 hours. (C) Immunofluorescence analysis of AR expression in 2 SCC-derived 
CAF strains treated with different BET inhibitors (JQ1, OTX, iBET; 100 nM each) versus DMSO vehicle alone for 24 hours. Representative images are shown, and AR 
fluorescence intensity values for each individual cell are indicated with mean ± SD. Scale bar: 10 μm. n(cell measurements per condition) = 35; ***P < 0.005, 1-way 
ANOVA with Dunnett’s test. Data on additional CAF and HDF strains are available in Supplemental Figure 11. (D) EGFP-expressing SK-MEL-23 melanoma cells were 
admixed with CAFs followed by parallel injections into contralateral ears of NOD/SCID/IL2rg–/– mice (8–10 weeks old, females). After 4 days, mice were treated 
topically biweekly with 20 μl of JQ1 as in ref. 6 or ethanol (EtOH) alone. Left panel: Representative images of combined bright-field and fluorescence microscopy of 
2 mouse ear pairs at 15 days after injection. Scale bar: 1 mm. Middle panel: Representative images of H&E staining of parallel ear lesions treated with EtOH or JQ1 
at the end of the experiment. Scale bar: 200 μm. Right panel: Quantification of green fluorescence intensity signal (intensity × surface area) of injected mouse ear 
pairs at the indicated time points after signal normalization on day 1. Data are represented as mean ± SEM. n(ear pairs) = 4; *P < 0.05, 2-tailed paired t test.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 4 jci.org
with a lentiviral expression vector for constitutive expression of AR, 
a gift of Karl-Henning Kalland (Bergen University, Bergen, Norway), 
in parallel with LacZ as control. RNAi experiments were carried out 
using shRNA-targeting lentiviral vectors from MilliporeSigma (for 
CSL, AR), as previously described (5). The details of the vectors used 
for RNAi are given in Supplemental Table 3.
For drug treatment 24 hours after seeding, HDFs or CAFs were treat-
ed with 100 nM JQ1 (Adooq Biosciences) or DMSO as control, or 10 μM 
MK-2866 (Selleckchem) or EtOH as control, for 24 hours before lysis. 
Flutamide (1 μM) treatment (Santa Cruz Biotechnology), or EtOH as con-
trol, was carried out for 48 hours before lysis. For testosterone treatments, 
HDFs or CAFs were washed 4 times in PBS after seeding and left 48 hours 
in phenol red–free DMEM complemented with hormone-stripped FBS 
(Thermo Fisher Scientific) before treatment with 20 nM DHT (Milli-
poreSigma) for 24 hours for HDFs and for 3 or 7 days for CAFs. SK-MEL-23 
melanoma cells were treated with 100 nM JQ1 (Adooq Biosciences) or 
DMSO for 24 hours for 5-ethynyl-2′-deoxyuridine (EdU) assay.
cin. Conditions of HDF and CAF isolation were previously reported 
(33). Human pancreatic stellate cells were maintained in stellate cell 
medium supplemented with 2% (vol/vol) FBS, 1% penicillin/strepto-
mycin, and 1% stellate growth supplement (ScienCell). All cells were 
grown at 37°C in the humidified incubator (Thermo Fisher Scientific) 
with 5% CO2. Cell lines were routinely tested to exclude mycoplasma 
contamination. Information regarding HDF strains and cell lines is 
reported in Supplemental Tables 4 and 5.
Skin SCC13 cells were originally reported in ref. 45, and CAL27 
were originally provided by Genrich Tolstonog (University Hospital 
of Lausanne, Lausanne, Switzerland). For in vivo approaches, SCC13 
and CAL27 cells were infected with an EGFP-expressing lentivirus (5), 
while SK-MEL-23 cells were concomitantly infected with RFP- and 
GFP-expressing fluorescence ubiquitination cell cycle indicator (FUC-
CI) viruses (28). HDF and CAF strains were stably infected with a len-
tiviral expression vector for constitutive expression of Myc-tagged 
CSL in parallel with empty vector control. CAF strains were infected 
Figure 13. Reversal of CAF activation by AR overexpression. (A) Multiple CAF strains infected with an AR-overexpressing lentivirus (pLenti AR) versus 
a β-galactosidase–expressing control (pLenti LacZ) were analyzed by RT-qPCR for expression of the indicated genes. Values for each strain are indicated 
as dots with mean ± SD. n(HDF strains) = 3; ***P < 0.005, 2-tailed unpaired t test. (B) Immunoblot analysis of AR versus CSL protein expression in 2 
CAF strains infected with an AR-overexpressing lentivirus (AR) versus control (LacZ). Blots were sequentially probed with antibodies against AR and 
γ-tubulin and, on a separate membrane, CSL and β-actin. αSMA regulation by AR overexpression in CAF strains is shown in Supplemental Figure 12A. 
(C) SCC13 cells were cocultured at a 1:1 ratio with HDF PB1 or CAF16 infected with β-galactosidase–expressing (pLenti LacZ) or AR-expressing (pLenti 
AR) lentiviruses for 3 days, followed by immunofluorescence analysis with anti-keratin (red) and anti-vimentin (green) antibodies for cell identification. 
Shown are representative images together with quantification of large SCC13 cell clusters (>40 cells) per examined field with mean ± SD. Scale bar: 200 
μm. n(number of fields) = 10; ***P < 0.005, 1-way ANOVA with Dunnett’s test. (D) SCC13 cells were mixed at a 1:1 ratio with HDF PB1 or β-galactosidase–
expressing (pLenti LacZ) versus AR-expressing (pLenti AR) CAF16 and grown in Matrigel 3D cultures for 5 days. Shown are representative images of 
SCC13 spheroids together with quantification by ImageJ software of spheroid diameter with mean ± SD. Scale bar: 250 μm. n(number of spheroids) = 50; 
***P < 0.005, 1-way ANOVA with Dunnett’s test.
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ChIP tagmentation (ChIPmentation) (47) and qPCR analysis were car-
ried out using anti-AR antibodies (Santa Cruz Biotechnology) versus 
nonimmune IgGs, starting from 15 × 106 HDFs. The immunoprecip-
itation of the sonicated chromatin was carried out using a previously 
described protocol (6). The bead-bound chromatin was tagged with 
Gene expression studies, LCM, ChIP, ChIPmentation, and re-ChIP 
studies. Gene expression and conditions of LCM studies were carried 
out as previously described (5, 33).
ChIP assay for histone modification of H3K27Ac, H3K9Me3, 
H3K36Me, and POLII was carried out as previously described (46). 
Figure 14. AR overexpression restrains in vivo CAF tumor-promoting ability. (A) EGFP-expressing SCC13 cells were admixed with CAFs with AR overexpression 
(pLenti AR) versus control (pLenti LacZ), followed by parallel ear injection into contralateral NOD/SCID/IL2rg–/– mice (8–10 weeks old, females). Shown is a quanti-
fication of the green fluorescence intensity signal (intensity × surface area) at the indicated time points after signal normalization on day 1. Data are represented 
as mean ± SEM. n(tumor pairs) = 7; *P < 0.05, **P < 0.01, 2-tailed paired t test. (B) Immunofluorescence analysis and quantification of Ki67- and keratin-positive 
cells in lesions formed by SCC13 cells admixed with CAFs with or without AR overexpression. Scale bar: 30 μm. Data are represented as mean ± SD. n(tumor pairs) 
= 3; *P < 0.05, 2-tailed paired t test. (C–F) Immunofluorescence analysis and quantification of the indicated markers in lesions formed by SCC13 cells admixed with 
CAF16 with or without AR overexpression. Shown are representative images and quantification for 3 ear pairs, examining at least 3 independent fields per lesion, 
using ImageJ software. Scale bars: 60 μm. Values are expressed as percentage of surface area positive for the indicated markers. Data are represented as mean ± 
SD. n(tumor pairs) = 3; *P < 0.05, 2-tailed paired t test. For analysis of SCC terminal differentiation markers, see Supplemental Figure 12, B and C.
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[Roche]). The lysate was precleared by centrifugation, and the superna-
tant was incubated with anti-CSL antibodies (Cell Signaling) or nonim-
mune IgGs overnight at 4°C. RNA-protein complexes were captured with 
antibody-coupled protein A magnetic beads, washed with RIP buffer, and 
treated with RNase-free DNase I. RNAs were isolated using the Trizol 
method. Approximately 200 ng of RNA from both immunoprecipitation 
and mock (nonimmune IgG) pull-down was converted to cDNA using ran-
dom hexamer primer. The RT-qPCR was carried out with lncRNA-specif-
ic primers, and fold enrichment was calculated against mock.
Tumorigenesis experiments. Mouse intradermal tumorigenicity ear 
injection assays were carried out in 8- to 10-week-old female NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (The Jackson Laboratory), as in 
ref. 5. Assays were conducted with the indicated combinations of cells: 
EGFP-expressing SCC13 cells (1 × 105), EGFP-expressing CAL27 cells 
(1 × 105), FUCCI-expressing SK-MEL-23 cells (1 × 105), or SK-MEL-28 
cells expressing dsRed (1 × 105) were admixed with equal numbers of 
HDFs with or without shRNA-mediated silencing of AR or with CAFs 
with or without AR overexpression. Cells were injected 5 μl per site 
using a 33-gauge microsyringe (Hamilton).
Data and software availability. Data sets generated for this study 
were deposited in the NCBI Gene Expression Omnibus (GEO) public 
repository (GSE107319, “Androgen receptor functions as transcriptional 
repressor of Cancer Associated Fibroblast (CAF) activation [RNA-seq]”).
Statistics. Data are presented as mean ± SEM or mean ± SD, as indi-
cated in the legends. For qPCR gene expression assays, histograms rep-
resent the value of each single strain. For gene expression and functional 
testing assays, statistical significance of differences between experimen-
tal groups and controls was assessed by 2-tailed unpaired or paired t test 
or by 1-way ANOVA with Dunnett’s test to correct for multiple compar-
isons, as indicated in the figure legends. A P value less than 0.05 was 
considered as statistically significant. For each experiment, at least 3 
separate HDF strains were used in the independent experiments. For 
ChIP–re-ChIP experiments, because of the complexity of the setting, the 
experiment was carried out in 1 strain. For ChIP assay regarding the AR 
histone modifications of AR promoter, 2 strains were used.
For ear injection/tumorigenicity assays, the individual animal vari-
ability issue was minimized by contralateral ear injections of the same 
animals with control versus experimental combinations of cells. No sta-
tistical method was used to predetermine sample size in animal experi-
ments. No exclusion criteria were adopted for studies and sample collec-
tion. No randomization was used, and the researchers were not blinded.
Study approval. HDFs were prepared from discarded human skin 
samples from abdominoplasty or circumcision at the Department of 
Surgery or Pediatrics, Lausanne University, with required institutional 
approvals (UNIL: CER-VD 222/12) and informed consent. Matched 
normal human skin samples and samples of SCCs were obtained at the 
Department of Dermatology, Massachusetts General Hospital, as dis-
carded parts not needed for diagnosis. All samples were processed as 
approved by the institutional review board (MGH: 2000P002418) and 
as described in refs. 5, 33. Matched normal skin and AK sections were 
provided by the Department of Dermatology, University of Tubingen, 
with institutional review board approvals and informed consent, as pre-
viously reported in ref. 5. Dysplastic nevus skin sections were obtained 
from the Department of Dermatology, University Hospital Zürich, with 
institutional review board approvals and informed consent. Experi-
ments on human-derived material followed the principles of the Decla-
ration of Helsinki as well as the Swiss laws governing human research. 
Tn5 transposase (Nextera DNA Sample Prep kit, Illumina) (47). The 
“tagmented” chromatin was de-cross-linked and subjected to protein-
ase K digestion. Equal amounts of recovered DNA (5 ng) were subject-
ed to amplification with tag-specific primers (14 cycles). Tag-specific 
PCR products were diluted (1:10), and 1 μl was used as a template for 
qPCR to determine the enrichment of the indicated sites; the primer 
sequences are listed in Supplemental Table 3.
For re-ChIP assays, bead-bound chromatin samples, recovered 
after immunoprecipitation with either anti-CSL or nonimmune IgGs, 
were subjected to tagmentation and eluted in 2% SDS, 15 mM DTT in 
1× TE buffer. Eluted products were diluted in immunoprecipitation buf-
fer (Tris-HCl, pH 8.0, 1 mM EDTA, 150 mM NaCl, 0.1% Triton X-100, 
1 mM PMSF, 1× protease inhibitors) and subjected to a second round of 
ChIP (re-ChIP) with anti-AR antibodies. After washing, the bead-bound 
chromatin fragments were de-cross-linked and eluted using proteinase 
K digestion. The eluted DNAs were amplified and subjected to ChIP-qP-
CR with specific primers (Supplemental Table 3) as described above. 
The enrichment (log2-fold) in ChIP or re-ChIP over nonimmune IgGs is 
indicated as relative chromatin binding. Regulatory regions in the IL6, 
POSTN, PLOD2, FAP, TGFBR1, TP53, and AR genes were identified by 
loading of available track information for H3K4Me3 (for promoter) and 
H3K4Me1 (for enhancer elements) from data deposited in the Encyclo-
pedia of DNA Elements at UCSC (ENCODE) for adult HDFs using the 
University of California, Santa Cruz (UCSC) Genome Browser (https://
genome.ucsc.edu/encode/). Putative AR and CSL binding sites in the 
regulatory regions of the TP53, IL6, POSTN, PLOD2, FAP, and TGFBR1 
genes were predicted using Matinspector (Genomatix).
Cell and coculture assays, immunoblots, and immunofluorescence. 
Immunoblots and immunofluorescence analyses were performed as 
previously described (5, 33). For 2D coculture assays, SCC13 and fibro-
blast cells were mixed (1:1 ratio) in complete DMEM containing 10 
% Matrigel (BD Biosciences) and plated onto 8-chamber glass slides 
(Corning). The cells were allowed to grow for 4 days in regular culture 
conditions. At the end of the experiment, the medium was removed 
from the glass slides, adherent cells were fixed with 4% paraformal-
dehyde and washed with PBS, and immunofluorescence staining was 
carried out with anti-vimentin (for fibroblasts) and anti–pan-keratin 
(for SCC13) antibodies. The slides were imaged using a Zeiss LSM880 
confocal microscope with a ×20 objective. The images were processed 
in ZEN Black software, and the number of large SCC13 cell clusters 
(>40 cells) was counted per field manually.
For 3D coculture assays, the SCC13 and fibroblast cells were 
mixed and plated onto 8-well chamber slides precoated with Matrigel 
(BD Biosciences). In brief, 8-well chambers were coated with 100 μl 
Matrigel per well and incubated for 30 minutes to polymerize at 37°C. 
The SCC13 cells and the fibroblasts were mixed at a 1:1 ratio in com-
plete DMEM with 1% Matrigel and overlaid on polymerized Matrigel 
chambers. The spheroids were allowed to grow for 6 days and ana-
lyzed using an EVOS Cell Imaging System (Thermo Fisher Scientific). 
The diameter of the spheroids was measured using ImageJ (NIH). See 
complete unedited blots for Figures 3–6, 10–13, and Supplemental Fig-
ures 3, 8, and 11 in the supplemental material.
RNA immunoprecipitation. RNA immunoprecipitation (RIP) assay 
was carried out as described in ref. 48 with minor modifications. Brief-
ly, HDFs were lysed in RIP buffer (10 mM Tris-HCl, pH 7.5, 0.5% Noni-
det P-40, 150 mM NaCl, 2 mM MgCl2, 1 mM DTT, 0.1 mM EDTA, 10% 
glycerol, 100 U/ml RNase inhibitor, and 1× protease inhibitor cocktail 
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performed the bioinformatics analysis. ML, PK, RD, and VN pro-
vided clinical samples. AC, SG, and GPD designed the study and 
wrote the manuscript.
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